These statements are based on management's current assumptions and beliefs in light of the information currently available to it and involve known and unknown risks and uncertainties. In this press release, statements made with respect to current plans, estimates, strategies and beliefs and other statements that are not historical facts are forward-looking statements about the future performance of Astellas. For more information, please visit our website at. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. Total number of shares acquired: 27,232,300 sharesДЄggregate amount of acquisition cost: 37,837,631,900 yenДЄstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Period of acquisition: From Jto October 31, 2017ДЄccumulated Company's own shares acquired through August 31, 2017, pursuant to the above board resolution (The percentage compared to the total number of shares outstanding: 2.42%)ДЄggregate amount of acquisition cost: Up to 70 billion yen Total number of shares to be acquired: Up to 50 million shares Method of acquisition: Purchased on the Tokyo Stock Exchange (Reference)Дetails of the resolution at the meeting of the Board of Directors (announced on July 28, 2017)Д¬lass of shares to be acquired: Common stock of the Company Total number of shares acquired: 26,037,300 sharesДЄggregate amount of acquisition cost: 36,161,707,500 yenДate of acquisition: From Augto August 31, 2017 The acquisition was implemented pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.Д¬lass of shares acquired: Common stock of the Company (TSE: 4503, President and CEO: Yoshihiko Hatanaka, 'the Company') announced the status of acquisition of its own shares as stated below. Tokyo, September 1, 2017- Astellas Pharma Inc. (Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act) It will also notify you if the changes made successfully completed or not via a popup result window.Astellas Announces Status of Acquisition of Own Shares Any modifications that you make can be overwritten to the original file or saved to a new file. You can also change the page layout and mode. You can open a PDF document (no drag n' drop support), and it will promptly display the current metadata and then allows quick and easy modification of any fields.ДЄdept PDF Info Changer also permits you to hide the toolbar, menu bar, and window UI, display the document title, resize the window to the first-page size, and center it. Once you run Adept PDF Info Changer, you are provided with a single window interface that contains all the fields needed to change the PDF file properties/metadata information, including author, title, subject, keywords, etc. Adept PDF Info Changer provides a simple way to change various aspects of a PDF document easily without the need of Adobe Acrobat and Reader.

Astellas pdf info